How to buy Iovance Biotherapeutics stock (IOVA)

Iovance Biotherapeutics is a biotechnology business based in the US. Iovance Biotherapeutics shares (IOVA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.38 – a decrease of 5.75% over the previous week. Iovance Biotherapeutics employs 557 staff and has a trailing 12-month revenue of around $90.9 million.

Our top picks for where to buy Iovance Biotherapeutics stock

Buy Iovance Biotherapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Iovance Biotherapeutics stock price (NASDAQ: IOVA)

Use our graph to track the performance of IOVA stocks over time.

Iovance Biotherapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$7.38
52-week range	$6.70 - $18.33
50-day moving average more info button	$9.55
200-day moving average more info button	$10.39
Wall St. target price	$23.77
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.48

Is it a good time to buy Iovance Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Iovance Biotherapeutics price performance over time

Historical closes compared with the close of $7.38 from 2024-12-20

1 week (2024-12-13)	-5.75%
1 month (2024-11-22)	-13.68%
3 months (2024-09-20)	-27.29%
6 months (2024-06-21)	-7.87%

1 year (2023-12-22)	-11.51%
2 years (2022-12-22)	21.38%
3 years (2021-12-22)	19.83
5 years (2019-12-20)	29.41

Iovance Biotherapeutics financials

Revenue TTM	$90.9 million
Gross profit TTM	$0
Return on assets TTM	-29.16%
Return on equity TTM	-56.65%
Profit margin	0%
Book value	$2.54
Market Capitalization more info button	$2.2 billion

TTM: trailing 12 months

Iovance Biotherapeutics share dividends

We're not expecting Iovance Biotherapeutics to pay a dividend over the next 12 months.

Have Iovance Biotherapeutics's shares ever split?

Iovance Biotherapeutics's shares were split on a 1:100 basis on 25 September 2013 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Iovance Biotherapeutics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Iovance Biotherapeutics shares which in turn could have impacted Iovance Biotherapeutics's share price.

Iovance Biotherapeutics share price volatility

Over the last 12 months, Iovance Biotherapeutics's shares have ranged in value from as little as $6.7 up to $18.33. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Iovance Biotherapeutics's is 0.594. This would suggest that Iovance Biotherapeutics's shares are less volatile than average (for this exchange).

Iovance Biotherapeutics overview

Iovance Biotherapeutics, Inc. , a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc. ; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.

Frequently asked questions

What percentage of Iovance Biotherapeutics is owned by insiders or institutions?
Currently 0.583% of Iovance Biotherapeutics shares are held by insiders and 88.498% by institutions. How many people work for Iovance Biotherapeutics?
Latest data suggests 557 work at Iovance Biotherapeutics. When does the fiscal year end for Iovance Biotherapeutics?
Iovance Biotherapeutics's fiscal year ends in December. Where is Iovance Biotherapeutics based?
Iovance Biotherapeutics's address is: 825 Industrial Road, San Carlos, CA, United States, 94070 What is Iovance Biotherapeutics's ISIN number?
Iovance Biotherapeutics's international securities identification number is: US4622601007 What is Iovance Biotherapeutics's CUSIP number?
Iovance Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 37182R102